Adam D. Levy
Known title: Chief Financial OfficerCIK: 0002061876
Adam D. Levy's purchase track record
Adam D. Levy has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 1/14/2026 | ACRV | $15K | -8.7% | +4.9% | +9.3% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| ACRV | ▼ Sell | Open Market | 1,142 | $2K | 8/4/2026 | View on chart |
| ACRV | ▲ Buy | Grant | 46,167 | $0 | 5/18/2026 | View on chart |
| ACRV | ▲ Buy | Open Market | 8,832 | $15K | 1/14/2026 | View on chart |
| ACRV | ▼ Sell | Tax Withholding | 1,164 | $1K | 8/1/2025 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 15, 2026
Acrivon Therapeutics noted among health‑care stocks moving in after‑market
Acrivon Therapeutics (ACRV) was included in a Benzinga roundup of twelve health‑care stocks that showed price movement during Wednesday’s after‑market session. The mention signals recent trading activity after regular hours. The stock is currently near its 52‑week low and its RSI is below 40, suggesting limited momentum.
Acrivon Therapeutics noted among health‑care stocks moving in after‑market. Acrivon Therapeutics (ACRV) was included in a Benzinga roundup of twelve health‑care stocks that showed price movement during Wednesday’s after‑market session. The mention signals recent trading activity after regular hours. The stock is currently near its 52‑week low and its RSI is below 40, suggesting limited momentum.